Genistein effect on cognition in prodromal Alzheimer’s disease patients. The GENIAL clinical trial

Abstract Background Delaying the transition from minimal cognitive impairment to Alzheimer’s dementia is a major concern in Alzheimer’s disease (AD) therapeutics. Pathological signs of AD occur years before the onset of clinical dementia. Thus, long-term therapeutic approaches, with safe, minimally...

Full description

Bibliographic Details
Main Authors: José Viña, Joaquín Escudero, Miquel Baquero, Mónica Cebrián, Juan Antonio Carbonell-Asíns, José Enrique Muñoz, Encarnación Satorres, Juan Carlos Meléndez, José Ferrer-Rebolleda, Mª del Puig Cózar-Santiago, Jose Manuel Santabárbara-Gómez, Mariona Jové, Reinald Pamplona, Francisco José Tarazona-Santabalbina, Consuelo Borrás
Format: Article
Language:English
Published: BMC 2022-11-01
Series:Alzheimer’s Research & Therapy
Subjects:
Online Access:https://doi.org/10.1186/s13195-022-01097-2

Similar Items